Modality
mAb
MOA
CDK2i
Target
SHP2
Pathway
Sphingolipid
T2DParkinson'sUC
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
Oct 2019
→ Sep 2031
Phase 1Current
NCT08589371
2,799 pts·UC
2019-10→2031-09·Not yet recruiting
NCT07778139
2,646 pts·Parkinson's
2025-04→2026-02·Terminated
5,445 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-122mo agoInterim· Parkinson's
2031-09-185.5y awayInterim· UC
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Not yet…
P1
Termina…
Catalysts
Interim
2026-02-12 · 2mo ago
Parkinson's
Interim
2031-09-18 · 5.5y away
UC
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08589371 | Phase 1 | UC | Not yet recr... | 2799 | OS |
| NCT07778139 | Phase 1 | Parkinson's | Terminated | 2646 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A |